论文部分内容阅读
[目的]探讨survivin基因启动子区rs9904341位点多态性与肺癌发生风险和晚期非小细胞肺癌(NSCLC)患者铂类药物化疗疗效的关系。[方法]通过聚合酶链反应—限制性酶切片断多态性方法(PCR-RFLP)检测289例健康对照组和289例肺癌患者的rs9904341多态性的基因型;其中130例晚期NSCLC仅接受铂类药物化疗,分析经2个周期化疗后的疗效及基因型与铂类药物化疗疗效和生存期的关系。[结果]基因型CC、CG、GG在肺癌组的分布频率分别为29.07%、47.05%、23.87%,在对照组的分布频率分别为20.42%、51.9%、27.68%,两组无显著性差异(P=0.053)。肺癌组中C等位基因和CC基因型的分布均显著高于对照组(P<0.05)。rs9904341多态性与晚期NSCLC患者铂类药物化疗有效率无显著相关性,但与临床受益率相关,GG基因型携带者的临床受益率是CC基因型者的2.06倍(95%CI:0.71～5.97,P=0.184)。对289例肺癌患者生存分析显示,CC基因型肺癌患者较CG+GG基因型预后差(95%CI:1.11～2.6,P=0.015)。[结论]rs9904341多态性与肺癌的发病风险、预后及晚期NSCLC患者铂类药物化疗临床受益率相关。
[Objective] To investigate the relationship between rs9904341 polymorphism in the promoter region of survivin gene and the risk of lung cancer and the efficacy of platinum-based chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). [Methods] The genotypes of rs9904341 polymorphism in 289 healthy controls and 289 lung cancer patients were detected by polymerase chain reaction-restriction fragment polymorphism (PCR-RFLP). Among them, 130 cases with advanced NSCLC accepted only Platinum drug chemotherapy, analysis of the efficacy of 2 cycles of chemotherapy and genotype and platinum drug efficacy and survival of the relationship. [Results] The distribution frequencies of genotypes CC, CG and GG in lung cancer were 29.07%, 47.05% and 23.87% respectively, and those in control group were 20.42%, 51.9% and 27.68% respectively, with no significant difference between the two groups (P = 0.053). The distribution of C allele and CC genotype in lung cancer group were significantly higher than that in control group (P <0.05). There was no significant correlation between rs9904341 polymorphism and chemotherapy efficacy in patients with advanced NSCLC, but the clinical benefit rate of patients with GG genotype was 2.06 times (95% CI: 0.71 ~ 5.97, P = 0.184). Survival analysis of 289 lung cancer patients showed that patients with CC genotype had a poorer prognosis than those with CG + GG genotype (95% CI: 1.11-2.6, P = 0.015). [Conclusion] The rs9904341 polymorphism is associated with the risk of lung cancer, the prognosis and the clinical benefit rate of platinum chemotherapy in patients with advanced NSCLC.